Cemiplimab for metastatic squamous cell carcinoma of the orbit, periocular adnexa, and thigh

References

• Soura E, Gagari E, Stratigos A. Advanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available? Curr Opin Oncol. 2019;31(5):461–468. doi:10.1097/CCO.0000000000000566.
   PubMed Web of Science ®Google Scholar
• Corneli P, Conforti C, Retrosi C, Vezzoni R, di Meo N, Piccolo V, et al. Pattern of response of unresectable and metastatic cutaneous squamous cell carcinoma to programmed death-1 inhibitors: a review of the literature. Dermatol Ther. 2020;33(2):e13250. doi:10.1111/dth.13250.
   PubMed Web of Science ®Google Scholar
• Lee A, Duggan S, Ed D. Cemiplimab: a review in advanced cutaneous squamous cell carcinoma. Drugs. 2020;80(8):813–819. doi:10.1007/s40265-020-01302-2.
   PubMed Web of Science ®Google Scholar
• Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341–351. doi:10.1056/NEJMoa1805131.
   PubMed Web of Science ®Google Scholar
• Rischin D, Migden MR, Lim AM, Schmults CD, Khushalani NI, Hughes BGM, et al. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer. 2020;8(1):e000775. doi:10.1136/jitc-2020-000775.
   PubMed Web of Science ®Google Scholar
• Rischin D, Khushalani NI, Schmults CD, Guminski A, Chang ALS, Lewis KD, et al. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. J Immunother Cancer. 2021;9(8):e002757. doi:10.1136/jitc-2021-002757.
   PubMed Web of Science ®Google Scholar
• Donaldson MJ, Sullivan TJ, Whitehead KJ, Williamson RM. Squamous cell carcinoma of the eyelids. Br J Ophthalmol. 2002;86(10):1161–1165. doi:10.1136/bjo.86.10.1161.
   PubMed Web of Science ®Google Scholar
• Yin VT, Merritt HA, Sniegowski M, Esmaeli B. Eyelid and ocular surface carcinoma: diagnosis and management. Clin Dermatol. 2015;33(2):159–169. doi:10.1016/j.clindermatol.2014.10.008.
   PubMed Web of Science ®Google Scholar
• Nasser QJ, Roth KG, Warneke C, Yin VT, El Sawy T, Esmaeli B. Impact of AJCC ‘T’ designation on risk of regional lymph node metastasis in patients with squamous carcinoma of the eyelid. Br J Ophthalmol. 2014;98(4):498–501. doi:10.1136/bjophthalmol-2013-304434.
   PubMed Web of Science ®Google Scholar
• El-Sawy T, Sabichi AL, Myers JN, Kies MS, William WN, Glisson BS, et al. Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma. Arch Ophthalmol. 2012;130(12):1608–1611. doi:10.1001/archophthalmol.2012.2515.
   PubMedGoogle Scholar
• Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011;29(25):3419–3426. doi:10.1200/JCO.2010.34.1735.
   PubMed Web of Science ®Google Scholar
• Foote MC, McGrath M, Guminski A, Hughes BGM, Meakin J, Thomson D, et al. Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Ann Oncol. 2014;25(10):2047–2052. doi:10.1093/annonc/mdu368.
   PubMed Web of Science ®Google Scholar
• Lewis CM, Glisson BS, Feng L, Wan F, Tang X, WistubasII, et al. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012;18(5):1435–1446. doi:10.1158/1078-0432.CCR-11-1951.
   PubMed Web of Science ®Google Scholar
• Gold KA, Kies MS, William WN, Johnson FM, Lee JJ, Glisson BS. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: a single arm phase II clinical trial. Cancer. 2018;124(10):2169–2173. doi:10.1002/cncr.31346.
   PubMed Web of Science ®Google Scholar
• Heath CH, Deep NL, Nabell L, Carroll WR, Desmond R, Clemons L, et al. Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2013;85(5):1275–1281. doi:10.1016/j.ijrobp.2012.09.030.
   PubMed Web of Science ®Google Scholar
• Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18(3):153–167. doi:10.1038/nri.2017.108.
   PubMed Web of Science ®Google Scholar
• Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563–580. doi:10.1038/s41571-019-0218-0.
   PubMed Web of Science ®Google Scholar
• Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, et al. Pilot phase II trial of neoadjuvant immunotherapy in locoregionally advanced, resectable cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2021;27(16):4557–4565. doi:10.1158/1078-0432.CCR-21-0585.
   PubMed Web of Science ®Google Scholar
• Schaffer M, Simonovich A, Livof A, Ostfeld I, Talisman R, Batash R, et al. Use of cemiplimab in locally advanced cutaneous squamous cell carcinoma. J Clin Case Rep. 2020;10(2):1320.
   Google Scholar
• Chang AL, Kim J, Luciano R, Sullivan-Chang L, Colevas AD. A case report of unresectable cutaneous squamous cell carcinoma responsive to pembrolizumab, a programmed cell death protein 1 inhibitor. JAMA Dermatol. 2016;152(1):106–108. doi:10.1001/jamadermatol.2015.2705.
   PubMed Web of Science ®Google Scholar
• McLean LS, Lim AM, Webb A, Cavanagh K, Thai A, Magarey M, et al. Immunotherapy to avoid orbital exenteration in patients with cutaneous squamous cell carcinoma. Front Oncol. 2022;11:796197. doi:10.3389/fonc.2021.796197.
   PubMed Web of Science ®Google Scholar
• Nägeli M, Mangana J, Chaloupka K, Dummer R. Cutaneous SCC with orbital invasion: case series. J Eur Acad Dermatol Venereol. 2022;36(Suppl 1):59–62. doi:10.1111/jdv.17529. PMID: 34855245
   PubMedGoogle Scholar
• Yin VT, Pfeiffer ML, Esmaeli B. Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma. Ophthalmic Plast Reconstr Surg. 2013;29(2):87–92. doi:10.1097/IOP.0b013e3182831bf3.
   PubMed Web of Science ®Google Scholar
• Ganesan P, Ali SM, Wang K, Blumenschein GR, Esmaeli B, Wolff RA, et al. Epidermal growth factor receptor P753S mutation in cutaneous squamous cell carcinoma responsive to cetuximab-based therapy. J Clin Oncol. 2016;34(5):e34–7. doi:10.1200/JCO.2013.50.3516.
   PubMed Web of Science ®Google Scholar
• Siegel JD, Bhatia A, Ko CJ, Christensen SR. Concurrent development of high-stage cutaneous squamous cell carcinoma during complete response of metastatic cutaneous squamous cell carcinoma to programmed cell death protein 1 blockade with cemiplimab. JAAD Case Rep. 2021;18:23–25. doi:10.1016/j.jdcr.2021.10.009.
   PubMedGoogle Scholar